

Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086 CIN:L85100MH1973PLC289209

August 13, 2022

To,
Corporate Relations Department **BSE Limited,**Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001.

Scrip Code: 540788
Security ID: ASPIRA

Dear Sir/Madam,

Subject: Intimation of Continuation of Dr. Subhash Salunke (DIN: 07940567) as Independent Director of the Company as per Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015:

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform that, the Board of Directors in its meeting held on August 13, 2022, on the recommendation of the Nomination and Remuneration Committee, approved the continuation of Directorship of Dr. Subhash Salunke (DIN: 07940567) as an Independent Director of the Company up to September 28, 2023, being the date of expiry of his current term of office, notwithstanding that on April 19, 2023 he attains the age of seventy-five (75) years during his current term of office subject to the approval of members of the Company.

Further, in compliance with circular no. LIST/COMP/14/2018-19 issued by BSE Limited, we wish to confirm that Dr. Subhash Salunke has not been debarred from holding the office of Director by virtue of any SEBI order or any other authority. He is not related to any other Director or Key Managerial Personnel (KMP) of the Company.

Pursuant to SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, the disclosure as required is enclosed herewith.

Please take the above information on record and arrange for dissemination.

Thanking you,

Yours faithfully,

For ASPIRA PATHLAB & DIAGNOSTIC LIMITED

Priya Pandey

Company Secretary & Compliance Officer

Encl: As above



DIAGNO



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086 CIN:L85100MH1973PLC289209

Annexure

Disclosure of information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. no.	Particulars	D/CMD/4/2015 dated September 9, 2015 Disclosure
1.	Name of Director	Dr. Subhash Salunke (DIN: 07940567)
2.	Reason of Change	Dr. Subhash Salunke aged 74 years, is the Non-Executive, Independent Director of the Company. Dr. Salunke will attain the age of 75 years on April 19, 2023 and pursuant to Regulation 17(1A), the continuation of his Directorship will be subject to approval by the shareholders by way of a special resolution at the 49th Annual General Meeting of the Company.
3.	Date of Appointment	Continuation of Directorship of Dr. Salunke who will attain the
		age of 75 years on April 19, 2023.
4.	Term of appointment	Non-Executive, Independent Director
5.	Brief Profile	Dr. Subhash Salunke has been an effective and popular faculty in the subject of Preventive and Social Medicine (Community Medicine) for eight years and a postgraduate guide. Also, he was an adjunct Associate professor of Biological Sciences, human ecology at the University of Texas, USA – School of Public Health – from 1994 to 2000. His 30 years's experience in the Public Health Department spans from Deputy Director to Director General in the Health Services of Maharashtra. Most of his illustrative examples of achievements in contemporary Public Health emanate from his own personal experience. Being an achiever, he has experienced a meteoric rise in the field of Public Health. His stint with the WHO SEARO spanned from being Regional Advisor in 2005 to Assistant Regional Director in 2009, including three years as the WHO representative to Indonesia.
		He has shown leadership in designing the HIV/AIDS Control special programme (AVERT) with the assistance of USAID for Maharashtra State. He was one of the members of designing National AIDS Control Programme Phase II during 1999-2000 that was a major step in control of HIV/AIDS through the National Programme for Control of HIV/AIDS.
	Disclosure of	He is not related to any other Director or Key Managerial Personnel (KMP) of the Company.

